NCT03926143 2023-08-04
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Bayer
Phase 2 Terminated
Clinical Trials
3 trialsNCT02610140 2020-11-04
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Bayer
Phase 2 Completed
NCT02839681 2019-05-21
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated